Rebecca Dawson, DO
Family Medicine · Millville, NJNPI 1104353028
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,981 of the $27,630 with a category attached, or 83.2%. Novo Nordisk accounts for 92.6% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $13,197, more than ten times the $39 reported in 2019. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $152.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$26K
- Lilly USA, LLC$486
- Pfizer$322
- AbbVie$268
- Bayer$149
- Insulet Corporation$107
- plus $702 from 23 others
What the payments were for
- Speaking & faculty fees$22,98183%
- Travel & lodging$9023%
- Food & beverage$3,73614%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $25,597 |
| Lilly USA, LLC | 24 | $486 |
| Pfizer | 20 | $322 |
| AbbVie | 18 | $268 |
| Bayer | 6 | $149 |
| Insulet Corporation | 1 | $107 |
| Axsome Therapeutics, Inc. | 5 | $90 |
| AstraZeneca | 6 | $85 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Amgen | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| GSK | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Lemaitre Vascular, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Exact Sciences | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Smith+Nephew | 1 | $21 |
| Novartis | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $19 |
| Organon | 1 | $18 |
| Conmed Corporation | 1 | $16 |
| Intra-sana Laboratories | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,630 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $167,610 |
| MounjaroTirzepatide | 94 | $110,736 |
| FarxigaDapagliflozin Propanediol | 36 | $41,670 |
| WegovySemaglutide | 29 | $37,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,022 |
| JardianceEmpagliflozin | 15 | $15,412 |
| EliquisApixaban | 13 | $13,272 |
| KerendiaFinerenone | 13 | $8,291 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,532 |
| SteglatroErtugliflozin Pidolate | 12 | $4,380 |
| AlogliptinAlogliptin Benzoate | 12 | $2,405 |
| Levothyroxine Sodium | 72 | $2,016 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $1,633 |
| Atorvastatin Calcium | 99 | $1,553 |
| Rosuvastatin Calcium | 49 | $1,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $25,597 | $205,206165 claims |
| Lilly USA, LLCMounjaro | $486 | $110,73694 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $85 | $49,20348 claims |
| GSKTrelegy Ellipta | $42 | $22,02228 claims |
| PfizerEliquis | $322 | $13,27213 claims |
| BayerKerendia | $149 | $8,29113 claims |
| MerckSteglatro | $12 | $4,38012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Millville
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
- Sally MravcakJersey City$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.